CNCR
Loncar Cancer Immunotherapy ETF
NAV as of
4 Week: 9.71 - 11.32
52 Week: 9.24 - 15.18
Latest Closing Price
11.32
Premium / Discount
-0.77
Expense Ratio
0.79%
Investment Objective
The investment seeks to track the performance, before fees and expenses, of the Range Cancer Therapeutics Index (the “index”). The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts (“ADRs”) with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund’s total assets will be invested in the component securities of the index.
Main Fund Characteristics
Performance
| Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
|---|---|---|---|
| YTD | -17.55 | 1.86 | -9.44 |
| 1 Day | 2.86 | 0.00 | 0.00 |
| 1 Week | 6.69 | 3.32 | 2.02 |
| 1 Month | 14.92 | 13.27 | 1.12 |
| 3 Months | -7.63 | 17.53 | -0.44 |
| 6 Months | -15.71 | 21.25 | -0.74 |
| 1 Year | -23.92 | 29.59 | -0.81 |
| 2 Years | -57.82 | 52.07 | -1.11 |
| 3 Years | -64.89 | 58.73 | -1.10 |
| 5 Years | -47.24 | 76.77 | -0.62 |
| 10 Years | 0.00 | 0.00 | 0.00 |
Price History
Annual Performance Return
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
| Price (%) | 0.0000 | 0.0000 | 0.0000 | -25.3506 | 13.0974 | -20.2684 | 24.0699 | 36.2193 | -19.4051 | -41.8131 |
| Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
| Rank | 0.0000 | 0.0000 | 0.0000 | 98.0000 | 90.0000 | 100.0000 | 55.0000 | 20.0000 | 96.0000 | 98.0000 |
Dividend Frequency
Lastest Dividend
| Ex Date | Payment Date | Dividend Payout per unit |
|---|---|---|
| 28/12/2021 | 30/12/2021 | 1.8533 |
| 27/12/2017 | 01/01/2018 | 0.3502 |
Portfolio Data
Total Number of Holdings: 87
Number of Bond Holdings: 0
Number of Equity Holdings: 86
Total Market Value: 10,989,044
Portfolio Composition
Top 10 Holdings
| % Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
|---|---|---|---|---|---|
| 1 | POINT Biopharma Global Inc Ordinary Shares | 2.3281 | 14,160 | 0 | 182,522 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
| Size | % of portfolio |
|---|---|
| Giant | 1.18 |
| Large | 4.94 |
| Medium | 1.30 |
| Small | 18.65 |
| Micro | 64.82 |
Equity Style Box Breakdown
| 0 | 0 | 0 | Large |
| 0 | 0 | 0 | Mid |
| 0 | 0 | 0 | Small |
| Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
15.6045
Price/Book*
1.4302
Price/Sales*
1.7605
Price/Cash Flow*
11.7497
Dividend Yield*
0.1032
Growth Measures
Long-Term Earnings
9.4972
Historical Earnings
32.6978
Sales Growth
15.0088
Cash-Flow Growth
79.1280
Book-Value Growth
-9.5214
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
| Detail | Value |
|---|---|
| Average Effective Duration | 0 |
| Average Effective Maturity (Years)* | 0 |
| Average Credit Quality | 0 |
| Average Weighted Coupon* | 0 |
| Average Weighted Price* | 0 |
Bond Style Box Breakdown
| 0 | 0 | 0 | High | Quality |
| 0 | 0 | 0 | Med | |
| 0 | 0 | 0 | Low | |
| Ltd | Mod | Ext | ||
| Interest-Rate Sensitivity | ||||
Credit Quality
| Type | % Bonds |
|---|---|
| N.A | |
Bond Sector
Bond Maturity
| % Bonds | |
|---|---|
| N.A | |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.
